-

Actio Biosciences to Participate in Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Actio Biosciences, a biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced that management will participate in two upcoming investor conferences in November and December 2024. Details are as follows:

  • Stifel 2024 Healthcare Conference
    • Actio’s CEO David Goldstein, Ph.D., will participate in a fireside chat on Tuesday, November 19, 2024, at 4:10 p.m. ET, and one-on-one investor meetings
  • Wells Fargo Virtual Private Biotech Symposium
    • Management will participate in one-on-one investor meetings on Thursday, December 12, 2024

About Actio Biosciences

Actio Biosciences is leveraging advances in precision medicine to develop new therapeutics that target shared genetics in rare and common diseases—bringing meaningful medicines from one to many. Applying its expertise in genetics, drug discovery and data sciences, Actio seeks to identify programs where both biological and technical risk can be minimized to streamline the drug development process and bring forward exceptionally potent and precisely targeted therapeutics. Actio is advancing two lead rare disease programs with first-in-class potential for the treatment of Charcot-Marie-Tooth Disease, Type 2C (CMT2C) and genetic epilepsy. The CMT2C program is expected to enter a Phase 1 clinical trial in early 2025, with the genetic epilepsy program entering a Phase 1 clinical trial in 2025. Founded in October 2021, the San Diego-based company is led by leaders in genetics and drug development and backed by top healthcare investors. For more information, please visit ActioBiosciences.com and follow us on LinkedIn.

Contacts

Dan Budwick, 1AB
dan@1abmedia.com

Industry:

Actio Biosciences

Release Versions
English

Contacts

Dan Budwick, 1AB
dan@1abmedia.com

More News From Actio Biosciences

Actio Biosciences Announces Preclinical Data Highlighting Ability of ABS-1230 to Potently and Selectively Inhibit KCNT1 and Significantly Reduce Seizure Activity

SAN DIEGO--(BUSINESS WIRE)--Actio Biosciences, a clinical-stage biotechnology company advancing the translation of genetic insights into novel precision medicines, today announced preclinical data related to the company’s co-lead candidate ABS-1230, a selective small molecule KCNT1 inhibitor for the treatment of KCNT1-related epilepsy. The data are being presented today, December 5, in a platform presentation by Actio CSO David Breckenridge, Ph.D., from 3:30-5:45 p.m. at the American Epilepsy S...

Actio Biosciences to Present New Preclinical Data for ABS-1230, a KCNT1 Inhibitor for the Treatment of KCNT1-Related Epilepsy, at the American Epilepsy Society Annual Meeting

SAN DIEGO--(BUSINESS WIRE)--Actio Biosciences, a clinical-stage biotechnology company advancing the translation of genetic insights into novel precision medicines, today announced it will present new preclinical data from its ABS-1230 program for the treatment of KCNT1-related epilepsy in a platform presentation and poster session at the American Epilepsy Society (AES) Annual Meeting, being held December 5-9 in Atlanta. KCNT1-related epilepsy is a rare and often fatal pediatric developmental ep...

Actio Biosciences Announces First Participant Dosed in Phase 1 Clinical Trial of ABS-1230, a KCNT1 Inhibitor for the Treatment of KCNT1-Related Epilepsy

SAN DIEGO--(BUSINESS WIRE)--Actio Biosciences, a clinical-stage biotechnology company leveraging a novel approach to genetics and precision medicine to develop new small molecule therapeutics that target shared underlying biology in both rare and common diseases, today announced that the first participant has been dosed in the Phase 1a healthy volunteer clinical trial of ABS-1230 for the treatment of KCNT1-related epilepsy. KCNT1-related epilepsy is a rare, severe and often fatal pediatric deve...
Back to Newsroom